In our first weekly update on COVID vaccines, we consider how roll-out plans are being tweaked and when it's likely we'll start to see vaccines having an impact.
There is now a third vaccine that prevents COVID-19 infections. It isn't quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Experts from across The Conversation look at how COVID-19 vaccines will work, how they're being tested and manufactured, and what challenges there will be to rolling them out.
The dangers of poor disclosure.
Mongkolchon Akesin
The phase 3 trials of the University of Oxford/AstraZeneca vaccine have been paused because one participant became unwell. But we don't know for sure if the illness was a reaction to the vaccine.
The Australian government is working with two major pharmaceutical companies to facilitate the local production and supply of two different COVID-19 vaccines – if they're proven to be effective.
The vaccine hasn't completed phase 3 trials, so we can't be sure it will be safe and effective for all. The Australian government's deal is contingent on these trials being successful.
Global economic realities shouldn't deter African universities from continuing to push for massification. But they must do so armed with knowledge, lessons from elsewhere and strong funding models.